SCHEMBL2640841

SCHEMBL2640841

CC(C)S(=O)(=O)c1ccc(-c2cnc(N(C(=O)OC(C)(C)C)C(=O)OC(C)(C)C)c(-c3nnc(-c4ccc(CN(C)C(=O)O)cc4)o3)c2)cc1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ATR Q13535 12/20 0.38
GSK3B P49841 1/20 0.37
PRKDC P78527 1/20 0.37
NPC1 O15118 1/20 0.33
ALOX15 P16050 1/20 0.33
CASP1 P29466 1/20 0.33
NR1H4 Q96RI1 1/20 0.33
S1PR1 P21453 1/20 0.32
MAPK14 Q16539 1/20 0.32
MAP4K4 O95819 1/20 0.32
MINK1 Q8N4C8 1/20 0.32
TNIK Q9UKE5 1/20 0.32
PDPK1 O15530 1/20 0.32
KDM4E B2RXH2 1/20 0.32
MEN1 O00255 1/20 0.32
ALDH1A1 P00352 1/20 0.32
MAPT P10636 1/20 0.32
MAPK1 P28482 1/20 0.32
HTT P42858 1/20 0.32
KMT2A Q03164 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2637807 0.96 ATR (0.38) ATRGSK3BPRKDCNPC1ALOX15
SCHEMBL2640906 0.93 ATR (0.36) ATRGSK3BPRKDCNPC1ALOX15
SCHEMBL10310888 0.89 ATR (0.36) ATRGSK3BPRKDCNPC1ALOX15
SCHEMBL2640819 0.83 ATR (0.36) ATRNPC1NR1H4S1PR1MAPK14
SCHEMBL20420666 0.83 ATR (0.43) ATRGSK3BPRKDC
SCHEMBL2486124 0.79 ATR (0.42) ATRGSK3BPRKDC
SCHEMBL2640968 0.79 ATR (0.36) ATRNPC1S1PR1MAPK14PDPK1
SCHEMBL2640963 0.78 BACE1 (0.37) ATRGSK3BNPC1S1PR1MAPK14
SCHEMBL12183897 0.77 ATR (0.36) ATRNPC1S1PR1MAPK14PDPK1
SCHEMBL615316 0.75 ATR (0.43) ATRNPC1NR1H4KDM4EMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20150239874-A1 COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE VERTEX PHARMACEUTICALS INCORPORATED 2015-08-27 US disclosed
US-9096584-B2 Compounds useful as inhibitors of ATR kinase VERTEX PHARMACEUTICALS INCORPORATED (US) 2015-08-04 US disclosed
EP-2569284-B1 2-AMINOPYRIDINE DERIVATIVES USEFUL AS INHIBITORS OF ATR KINASE VERTEX PHARMA (US) 2015-07-08 EP disclosed
EP-2569284-A1 2 -AMINOPYRIDINE DERIVATIVES USEFUL AS INHIBITORS OF ATR KINASE Vertex Pharmaceuticals Incorporated (US) 2013-03-20 EP disclosed
US-20120177748-A1 COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE VERTEX PHARMACEUTICALS INCORPORATED (US) 2012-07-12 US disclosed
WO-2011143422-A1 2 -AMINOPYRIDINE DERIVATIVES USEFUL AS INHIBITORS OF ATR KINASE VERTEX PHARMACEUTICALS INCORPORATED (US) 2011-11-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150239874-A1 COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE ATR, CHEK1, MAP3K20 ATR 1/4885GSK3B 130/4885PRKDC 31/4885
US-20120177748-A1 COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE ATR, CHEK1, MAP3K20 ATR 1/4885GSK3B 130/4885PRKDC 31/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.